Regeneron Pharmaceuticals, Inc.
High concentration VEGF receptor fusion protein containing formulations

Abstract:

The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.